TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger T...(ive items related to the merger as to be...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
TorreyPines Cancels Special Meeting of Stockholders in Order to Pursue Merger Transaction
Date:7/30/2009
ive items related to the merger as to be set forth in the S-4. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines' other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Company contact:
Paul Schneider
TorreyPines Therapeutics, Inc.
858-623-5665 X125
'/>"/>
| SOURCE TorreyPines Therapeutics, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. TorreyPines Therapeutics Reports Third Quarter 2007 Results
7. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
8. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
Breaking Biology Technology:Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sirius Genomics Announces Change in Leadership 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
[0] Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease[0] Sirius Genomics Announces Change in Leadership[0] Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
Other Biology Technology:Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock 2Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock 3Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock 4Genencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic Ethanol 2Web-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues 2
Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common StockGenencor Launches Accellerase(R) 1500, Next Step Toward Scale-Up of Cellulosic EthanolWeb-based Audio Interviews Keep Environment of Care Managers Up-to-Date on Key EC Compliance Issues
Breaking Biology News(10 mins):Tropical birds waited for land crossing between North and South America: UBC study 277 percent of European pigs are castrated without anesthetic 2University of the Basque Country research on plankton at Urdaibai 2Canadian scientists link fat hormone to death from potentially deadly blood infection 59994 1Canadian scientists link fat hormone to death from potentially deadly blood infection 59994 2ARVO Foundation and Pfizer Ophthalmics honor Carl B Camras with translational research award 59992 1Evolution of hyperactivity is focus of free public lecture at UC Riverside 10504 1Evolution of hyperactivity is focus of free public lecture at UC Riverside 10504 2
Other Biology News:New southernpeas developed by ARS, cooperators 2Research cautions to catch-and-release in less than 4 minutes 2454 Sequencing uncovers a genetic basis for different social behaviors in wasp 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |